Pfizer Inc. reports developments across its global biopharmaceutical business, including prescription medicines, vaccines, biosimilars, sterile injectables, and oncology therapies. Recurring news covers financial results and guidance, commercial portfolio changes within Biopharma, dividend declarations, capital allocation priorities, and product access initiatives for established medicines such as Eliquis.
Company updates also address clinical and regulatory activity across Pfizer's pipeline and marketed products. Recent themes include oncology data presentations, Phase 3 results for ELREXFIO in relapsed or refractory multiple myeloma, PADCEV combination regulatory activity in bladder cancer, VYNDAMAX patent litigation settlements, and shareholder meeting communications.
Pfizer (PFE) will present 45 oncology research abstracts at the ESMO Congress in Madrid, running October 23–27, 2026. The program includes 11 oral presentations and covers breast, lung and genitourinary cancers.
Planned presentations include Phase 2 results for atirmociclib in advanced breast cancer and Phase 3 survival results for investigational sigvotatug vedotin in previously treated lung cancer. Pfizer will also present updated analyses of PADCEV-based treatment and TALAPRO-3 patient-reported outcomes and safety data. A supplemental application for TALZENNA plus XTANDI in metastatic castration-sensitive prostate cancer remains under FDA Priority Review.
Pfizer (PFE) will host a webcasted conference call with investment analysts at 10:00 a.m. EST on Tuesday, November 3, 2026, to discuss its Third Quarter 2026 Performance Report, which is scheduled to be issued that morning.
Investors and the public can access the live webcast and the Performance Report at www.pfizer.com/investors, where registration instructions are available beginning September 22, 2026. Participants are advised to register in advance. The call can also be joined by phone by dialing 800-456-4352 in the U.S. and Canada or 785-424-1086 outside these regions, using passcode 11974. A transcript and replay of the webcast will be posted on the investor website within 24 hours after the call and remain accessible for at least 90 days.
Pfizer (PFE) will host a webcast of a discussion with Chief International Commercial Officer and Executive Vice President Alexandre de Germay at the J.P. Morgan U.S. All Stars 2026 Conference on Tuesday, September 22, 2026, at 11:50 a.m. BST.
Investors and the public can access the live audio via the www.pfizer.com/investors website, where registration and access details are available beginning September 15, 2026. A transcript and replay of the webcast will be posted on the same site within 24 hours after the live discussion and will remain accessible for at least 90 days. Pfizer notes that the webcast may contain forward-looking statements subject to substantial risks and uncertainties, as described in its SEC filings.
Pfizer (PFE) will webcast a discussion with Chairman and CEO Albert Bourla at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026, at 10:45 a.m. EDT.
The live audio will be accessible through the investor section of Pfizer’s website at www.pfizer.com/investors, where access and registration details are available starting today. A transcript and replay of the webcast will be posted on the same site within 24 hours after the event and remain available for at least 90 days. Pfizer notes the webcast may contain forward-looking statements subject to risks described in its SEC filings.
Pfizer (NYSE:PFE) and Valneva (Nasdaq:VALN; Euronext Paris:VLA) announced that the European Medicines Agency has validated the Marketing Authorization Application for PF‑07307405, their 6‑valent OspA‑based Lyme disease vaccine candidate, and will now begin its formal assessment. The filing is supported by Phase 3 VALOR data showing more than 70% efficacy in preventing Lyme disease in participants aged five years and older, with the vaccine reported as well tolerated and with no safety concerns identified. According to the companies, PF‑07307405 targets six Borrelia OspA serotypes prevalent in North America and Europe, and is the most clinically advanced Lyme disease vaccine candidate, with two pivotal Phase 3 trials completed.
Pfizer (NYSE:PFE) reported second-quarter 2026 revenues of $15.0 billion, up 3% year over year (1% operational), with launched and acquired products delivering 18% operational revenue growth. Excluding Comirnaty and Paxlovid, revenues grew 5% operationally.
The quarter showed a Reported loss per share of $(0.04) driven by $4.3 billion in non-cash intangible asset impairments, while Adjusted diluted EPS was $0.77, roughly flat versus 2025. Pfizer raised its 2026 revenue guidance midpoint by $500 million to a range of $60.5–$62.5 billion, reflecting about $1.5 billion better-than-expected non-COVID sales and a revised COVID-19 revenue expectation of approximately $4 billion, down from about $5 billion.
The company reaffirmed 2026 Adjusted diluted EPS guidance of $2.80–$3.00, which incorporates a $650 million acquired IPR&D charge and roughly $0.10 EPS impact from the Innovent Biologics transaction. Pfizer also announced an additional $2.5 billion in anticipated productivity enhancement savings expected from 2027 through 2029 and highlighted strong growth from Eliquis, Padcev, the Vyndaqel family and Lorbrena, offset by steep declines in Paxlovid (down 95% operationally) and Comirnaty (down 34% operationally).
Pfizer (NYSE: PFE) reported positive topline Phase 3 results from two pivotal TRANQUILLO trials of once‑daily LITFULO (ritlecitinib) in patients with active or stable nonsegmental vitiligo (NSV). Both 50 mg and 100 mg doses met co‑primary endpoints, showing significant, clinically meaningful improvements in facial (F‑VASI75) and total body (T‑VASI50) repigmentation versus placebo at Week 52.
Across TRANQUILLO and TRANQUILLO 2, 2,174 patients were enrolled at 271 sites worldwide, including adolescents 12+ in TRANQUILLO and adults in TRANQUILLO 2. The NSV safety profile was consistent with LITFULO’s established alopecia areata profile, with no new safety signals. Based on these data, Pfizer plans global regulatory filings for an adult NSV indication.
Pfizer (NYSE:PFE) reported that the U.S. FDA has accepted for Priority Review a supplemental New Drug Application for TALZENNA (talazoparib) plus XTANDI (enzalutamide) to treat men with HRR gene‑altered metastatic castration‑sensitive prostate cancer (mCSPC). The FDA set a PDUFA action date in the last quarter of 2026. The regimen is already approved in the U.S. for HRR gene‑mutated metastatic castration‑resistant prostate cancer (mCRPC); approval of this filing would move use into an earlier disease setting.
The application is supported by Phase 3 TALAPRO‑3 data in 599 patients, where TALZENNA plus XTANDI reduced the risk of radiographic progression or death by 52% versus placebo plus XTANDI, showing consistent benefit across BRCA and non‑BRCA HRR alterations and no new safety signals. TALZENNA plus XTANDI for HRR‑mutated mCSPC is also under review by the European Medicines Agency. The release additionally outlines detailed safety information, including risks of myelodysplastic syndrome/acute myeloid leukemia, significant myelosuppression rates, embryo‑fetal toxicity, and important drug‑interaction and dosing guidance, particularly in renal impairment.
Pfizer (NYSE: PFE) and Astellas received U.S. FDA approval for PADCEV (enfortumab vedotin-ejfv) plus Keytruda (pembrolizumab or Keytruda QLEX) as neoadjuvant and adjuvant treatment for adult muscle-invasive bladder cancer (MIBC) regardless of cisplatin eligibility, creating the first platinum-free regimen for this setting.
The approval is based on Phase 3 EV-304 (KEYNOTE-B15) data, where PADCEV plus pembrolizumab showed a 47% reduction in risk of tumor recurrence, progression or death versus neoadjuvant gemcitabine/cisplatin (HR 0.53) and a 35% reduction in risk of death (HR 0.65). Event-free survival at two years was 79.4% versus 66.2% with standard chemotherapy, and pathological complete response was 55.8% versus 32.5%. The safety profile was consistent with prior experience, although grade ≥3 adverse events occurred in 75.7% of patients versus 67.2% with chemotherapy.
Pfizer (NYSE:PFE) declared a $0.43 third-quarter 2026 cash dividend on its common stock. The dividend is payable September 1, 2026 to shareholders of record on July 24, 2026. This will be Pfizer’s 351st consecutive quarterly dividend, supporting its strategy to maintain and, over time, grow dividends.